Clinical Trials at University of Arkansas Myeloma Institute

http://myeloma.uams.edu/about-myeloma/clinicaltrials.asp

UARK 2004-23, A Phase I Study of Multiple Intravenous Administrations of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects with B-cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease

Phase: I

Purpose: The purpose of this study is to evaluate five different doses and schedules of CNTO 328 to see which dose/schedule is safe.

Eligibility: Approximately 10 patients, male and female, age 18 and older, regardless of race or ethnicity, will participate in this study at UAMS.